10X GENOMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.42 USD | +0.04% |
|
-0.75% | -59.94% |
| 05-29 | 10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium | CI |
| 05-15 | Transcript : 10x Genomics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM |
| Sales 2024 * | 670M 911M | Sales 2025 * | 769M 1.05B | Capitalization | 2.68B 3.65B |
|---|---|---|---|---|---|
| Net income 2024 * | -190M -259M | Net income 2025 * | -119M -162M | EV / Sales 2024 * | 3.41 x |
| Net cash position 2024 * | 401M 546M | Net cash position 2025 * | 493M 670M | EV / Sales 2025 * | 2.85 x |
| P/E ratio 2024 * |
-14
x | P/E ratio 2025 * |
-22.7
x | Employees | 1,259 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on 10x Genomics, Inc.
More recommendations
More press releases
| 1 day | +0.04% | ||
| 1 week | -0.75% | ||
| 1 month | -14.72% | ||
| 3 months | -50.79% | ||
| 6 months | -50.99% | ||
| Current year | -59.94% |
1 week
21.74
22.90
1 month
21.7428.25
Current year
21.7455.96
1 year
21.7463.57
3 years
21.74208.99
5 years
21.74208.99
10 years
21.74208.99
| Managers | Title | Age | Since |
|---|---|---|---|
Serge Saxonov
FOU | Founder | 47 | 12-07-01 |
Ben Hindson
FOU | Founder | 49 | 12-07-01 |
Justin McAnear
DFI | Director of Finance/CFO | 49 | 18-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Stuelpnagel
CHM | Chairman | 66 | 13-07-31 |
Kim Popovits
BRD | Director/Board Member | 65 | 20-03-25 |
Mathai Mammen
BRD | Director/Board Member | 57 | 17-08-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 22.42 | +0.04% | 1,381,357 |
| 24-05-30 | 22.41 | +1.36% | 1,255,834 |
| 24-05-29 | 22.11 | -2.60% | 1,269,053 |
| 24-05-28 | 22.7 | +0.49% | 1,414,360 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm
More quotes
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Calendar
2024-06-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
22.42
USD
Average target price
41.14
USD
Spread / Average Target
+83.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -59.94% | 2.68B | |
| -3.17% | 8.22B | |
| +6.11% | 5.72B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B | |
| -7.56% | 1.8B | |
| +3.07% | 1.6B |
- Stock Market
- Equities
- TXG Stock
